A recent study demonstrated that genetic engineering of CD8+ T cells with CCR4 enhances their migration toward CCL22 secreted from Panc02 pancreatic cancer cells in vitro, and that adoptive transfer of the CCR4-engineered T cells into the Panc02 tumor-bearing mice eradicate the established tumor more efficiently than the infusion of non-engineered T cells (130). Here, CD8A is linked to neoplasm.